Arbutus Biopharma (ABUS) has released an update.
Arbutus Biopharma has expressed satisfaction with a U.S. District Court ruling in its patent infringement lawsuit against Moderna concerning the company’s proprietary lipid nanoparticle (LNP) technology used in Moderna’s COVID-19 vaccine. The court’s decision aligns with Arbutus’s interpretation of key patent claims and supports their position in seeking compensation for the use of their technology. Arbutus continues to defend its intellectual property rights as the litigation proceeds.
For further insights into ABUS stock, check out TipRanks’ Stock Analysis page.
